ARWR vs MOH

ARWR's Piotroski F-Score of 4/9 indicates weak financial health, with a notable debt/equity ratio of 1.24 and a lack of Altman Z-Score data, raising concerns about long-term solvency. However, the company exhibits exceptional profitability with a 75.5% ROE and 100% gross margin, supported by a staggering 10,461% YoY revenue growth. Despite a high current price of $55.05 and elevated valuation multiples (P/E: 34.41, P/S: 7.07), the stock trades at a premium due to explosive growth expectations. Analysts maintain a 'buy' consensus with a target price of $81.36, reflecting strong conviction in future upside. Insider selling activity, while bearish in sentiment, may reflect liquidity events rather than fundamental concerns.

Molina Healthcare exhibits a stable Piotroski F-Score of 5/9, but this is overshadowed by a severe collapse in profitability and earnings quality. The company is currently trading at $151.00, which is significantly above its growth-based intrinsic value of $62.79 and its defensive Graham Number of $126.90. A rising Medical Care Ratio (MCR) of 91.7% and negative operating margins (-1.49%) indicate that rising healthcare costs are outpacing state reimbursement rates. With a 1-year price decline of 50% and a catastrophic YoY EPS growth of -154.5%, the stock appears to be in a fundamental downtrend.